Literature DB >> 2777412

Stability of phenotypic and genotypic traits during the establishment of a human neuroblastoma cell line, IGR-N-835.

L Bettan-Renaud1, C Bayle, J R Teyssier, J Benard.   

Abstract

A prerequisite for the study of biological characteristics in neuroblastoma is the establishment of cell lines from tumors of patients. For our study a neuroblastoma cell line, IGR-N-835, was established from a primary tumor. During in vitro establishment of this line morphological changes were observed. IGR-N-835 exhibited both anchored cells and floating clusters. When cultured on bovine endothelial corneal cellular matrix, all tumor cells anchored to the matrix and proliferated, giving a continuous cell line. IGR-N-835 was studied in vitro and in vivo. Treatment with retinoic acid resulted in cell growth arrest and morphological differentiation. IGR-N-835 was highly tumorigenic in nude mice, exhibited a doubling time of 65 hr and was able to form colonies in methyl-cellulose with a cloning efficiency of 0.46%. Immunocytochemical studies showed reactivity of this line and its primary passages with CE7 monoclonal antibody (MAb). Cytogenetic analyses revealed stable mode and markers resulting from structural changes in chromosomes 10, 11 and 21 with no homogeneously staining regions or double minute chromosomes. Genomic amplification and overexpression of the N-myc oncogene exhibited by the patient's tumor remained unchanged in nude mouse xenografts and the IGR-N-835 cell line. These phenotypic and genotypic traits were unchanged during establishment of this neuroblastoma line. IGR-N-835 could therefore constitute a suitable material for the study of the biology or therapeutics of human neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2777412     DOI: 10.1002/ijc.2910440314

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries.

Authors:  Valentina Boeva; Caroline Louis-Brennetot; Agathe Peltier; Simon Durand; Cécile Pierre-Eugène; Virginie Raynal; Heather C Etchevers; Sophie Thomas; Alban Lermine; Estelle Daudigeos-Dubus; Birgit Geoerger; Martin F Orth; Thomas G P Grünewald; Elise Diaz; Bertrand Ducos; Didier Surdez; Angel M Carcaboso; Irina Medvedeva; Thomas Deller; Valérie Combaret; Eve Lapouble; Gaelle Pierron; Sandrine Grossetête-Lalami; Sylvain Baulande; Gudrun Schleiermacher; Emmanuel Barillot; Hermann Rohrer; Olivier Delattre; Isabelle Janoueix-Lerosey
Journal:  Nat Genet       Date:  2017-07-24       Impact factor: 38.330

2.  Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma.

Authors:  C-H Gattolliat; L Thomas; S A Ciafrè; G Meurice; G Le Teuff; B Job; C Richon; V Combaret; P Dessen; D Valteau-Couanet; E May; P Busson; S Douc-Rasy; J Bénard
Journal:  Br J Cancer       Date:  2011-10-04       Impact factor: 7.640

3.  Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.

Authors:  G Vassal; M J Terrier-Lacombe; M C Bissery; A M Vénuat; F Gyergyay; J Bénard; J Morizet; I Boland; P Ardouin; B Bressac-de-Paillerets; A Gouyette
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

4.  Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations.

Authors:  I Boland; G Vassal; J Morizet; M J Terrier-Lacombe; D Valteau-Couanet; C Kalifa; O Hartmann; A Gouyette
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

5.  Expression of two parental imprinted miRNAs improves the risk stratification of neuroblastoma patients.

Authors:  Charles-Henry Gattolliat; Gwénaël Le Teuff; Valérie Combaret; Eugénie Mussard; Dominique Valteau-Couanet; Pierre Busson; Jean Bénard; Sétha Douc-Rasy
Journal:  Cancer Med       Date:  2014-06-13       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.